Cardiac manifestations in a two‑generation family with Fabry disease (RCD code: III‑2B.2a)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2014, Vol 1, Issue 8
Abstract
Fabry disease (FD), which is also called angiokeratoma corporis difusum, ceramide trihexosidosis, and Anderson-Fabry disease, is an X-linked inborn error of metabolism of glycosphingolipid pathway. It is caused by the deficiency of the the lysosomal enzyme – hydrolasealpha-galactosidase A, which results in the accumulation and subsequent tissue deposition of globotriaosylceramide, the glycolipid substrate for alpha-galactosidase A. The incidence of the disease varies between 1:17,000 to 1:117,000 males in the Caucasian populations. The disease is less common among women, and if present the symptoms are milder. Enzyme replacement therapy of the agalsidase-A or agalsidase-ß offers a specific treatment for patients with FD. Since 2001 the ERT, using recombinant human alpha-galactosidase A, has become the most efficient and specific therapy, which address the underlying defect of FD. The guidelines on the ERT greatly vary among countries, the main reason being the high cost of this treatment. Pediatric patients firstly suffer from neurological involvement, manifesting as a persistent, neuropathic pain of the extremities, often misdiagnosed as a “growing pain”, as well as gastrointestinal disorders(diarrhea, nausea, vomiting). In the later stages other organs are becoming involved causing multi-organ failure renal insufficiency, cardiovascular impairment, cerebrovascular incidences, cutaneous changes (teleangiectasias, angiokeratomas and lymphoedema), malfunction of sensations organs (cornea verticillata, retinal vascular tortuosity) and other symptom like anhidrosis, sweating problems, heat collapse or depression. JRCD 2014; 1 (8): 27–31
Authors and Affiliations
Paweł Rubiś, Sylwia Wiśniowska-Śmiałek, Barbara Biernacka-Fijałkowska, Magdalena Kostkiewicz, Agata Leśniak-Sobelga, Piotr Podolec
Keywords
Related Articles
- EP ID EP245414
- DOI 10.20418/jrcd.vol1no8.155
- Views 128
- Downloads 0
JRCD is now an open‑access journal and also accepts high‑quality papers beyond the field of rare cardiovascular diseases and disorders
n/a
Pregnant woman with Eisenmenger’s syndrome (RCD code: VII-II-1A.4d)
Pregnancy in women with pulmonary arterial hypertension due to congenital heart disease is associated with significant morbidity and mortality both in the mother and fetus. We report a case of a 25-year-old woman with Ei...
“A rare day to put rare diseases in the spotlight!” “With research possibilities are limitless”
Just few days ago, on 28th February, the tenth edition of Rare Disease Day was launched by EURORDIS and its Council for National Alliances to attract thousands people all over the world to come together to advocate for m...
Myxoma of the heart (RCD code: VI-1A.1)
Myxomas are the most common primary benign intracardiac tumors. Typically they locate in the left atrium (LA) or right atrium (RA) and are composed of cells, that originate from multipotent mesenchyme. The clinical manif...
“Let (the hospital) serve!”. Pope John Paul II. Visit at the John Paul II Hospital in Krakow, 9 June 1997
This June, here in Krakow we witness two important anniversaries. First, our hospital, now called after Pope John Paul II, is already 100 years old. Secondly, 20 years have already passed since the visit on the hospital’...